利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

70 条记录 (耗时 0.03 秒)

    Modular transport platform for targeted delivery of therapeutic agents
    14.
    发明授权
    Modular transport platform for targeted delivery of therapeutic agents 有权
    用于靶向递送治疗剂的模块化运输平台

    公开(公告)号：US09095624B2

    公开(公告)日：2015-08-04

    申请号：US13371377

    申请日：2012-02-10

    申请人： Alexander S. Sobolev ,  Andrey A. Rosenkranz ,  David A. Jans ,  Vladimir G. Lunin

    发明人： Alexander S. Sobolev ,  Andrey A. Rosenkranz ,  David A. Jans ,  Vladimir G. Lunin

    IPC分类号： A61K31/40 ,  A61K38/41 ,  A61K51/00 ,  A61K47/48 ,  A61K41/00 ,  A61K51/08

    CPC分类号： A61K47/48269 ,  A61K41/0071 ,  A61K47/6415 ,  A61K47/642 ,  A61K47/6445 ,  A61K51/081 ,  A61K51/088

    摘要： The invention relates to a modular transport platform (MTP) configured to penetrate a target cell, deliver the MTP into the target cell, provide a pH dependent membrane disruption activity, direct intracellular transport into a target subcellular compartment of the target cell, and couple the active agent within the modular platform. The modular transport platform includes: (1) a ligand module to target a specific receptor on the surface of the target cell; (2) an endosomolytic module that provides pH-dependent membrane disruption activity within the target cell; (3) an intracellular transport module to cause delivery of the MTP to a particular subcellular compartment; (4) a module for intracellular retention; (5) a module for subcellular recognition; (6) a substance to be transported by the MTP; and (7) a carrier module for unifying the modules and coupling the modules with the transported substance.

    摘要翻译： 本发明涉及一种模块化传输平台（MTP），其被配置为穿透靶细胞，将MTP递送到靶细胞中，提供pH依赖性膜破坏活性，直接细胞内转运至靶细胞的靶亚细胞室，并将 活动代理在模块化平台内。 模块化运输平台包括：（1）靶靶细胞表面上的特定受体的配体模块; （2）在靶细胞内提供pH依赖性膜破坏活性的内体分解模块; （3）细胞内转运模块，以使MTP递送至特定的亚细胞室; （4）用于细胞内保留的模块; （5）用于亚细胞识别的模块; （六）中期计划运输的物质; 和（7）用于统一模块并将模块与输送的物质耦合的载体模块。

    PTEN inhibitor or Maxi-K channels opener
    16.
    发明授权
    PTEN inhibitor or Maxi-K channels opener 有权
    PTEN抑制剂或Maxi-K通道开放剂

    公开(公告)号：US07825130B2

    公开(公告)日：2010-11-02

    申请号：US10546632

    申请日：2004-02-24

    申请人： Ki Whan Hong

    发明人： Ki Whan Hong

    IPC分类号： A61K38/41

    CPC分类号： A61K31/4709

    摘要： A new PTEN opener or a new opener of a large conductance Ca2+-activated K+ channel (Maxi-K channel) which comprises as an active ingredient a tetrazolylalkoxy-dihydrocarbostyril compound of the formula (I): wherein R is cycloalkyl, A is lower alkylene, and the bond between 3- and 4-positions of the carbostyril nucleus is single bond or double bond, or a salt thereof, which is useful as a medicament for promotion of the survival of normal cells, brain cells, heart cells, and skin, and further for inhibiting of Gram negative sepsis and cell migration and cell invasion due to inhibition of PTEN and is further useful as a medicament for the treatment of neuronal disorders, for example, an anticonvulsant, a neuroprotecting agent, a medicament for treatment of regional cerebral edema and neurologic motor impairment, cognitive disorders, traumatic brain injury, Parkinson's disease, epilepsy, migraine, and Alzheimer's disease, etc.

    摘要翻译： 包含作为活性成分的式（I）的四唑基烷氧基 - 二氢喹诺酮化合物的新型PTEN开启剂或大电导Ca 2+激活的K +通道（Maxi-K通道）的新开启剂：其中R是环烷基，A是低级亚烷基 ，并且喹诺酮核的3-和4-位之间的键是单键或双键或其盐，其可用作促进正常细胞，脑细胞，心脏细胞和皮肤的存活的药物 ，并且进一步用于抑制由于抑制PTEN而引起的革兰氏阴性败血症和细胞迁移和细胞侵袭，并且还可用作治疗神经元病症的药物，例如抗惊厥药，神经保护剂，用于治疗区域的药物 脑水肿和神经运动障碍，认知障碍，创伤性脑损伤，帕金森病，癫痫，偏头痛和阿尔茨海默病等。

    Use of heme-peptides to prevent or retard disease associated with oxidative stress
    20.
    发明授权
    Use of heme-peptides to prevent or retard disease associated with oxidative stress 失效
    使用血红素肽预防或延缓与氧化应激相关的疾病

    公开(公告)号：US6013623A

    公开(公告)日：2000-01-11

    申请号：US807482

    申请日：1997-02-27

    申请人： Abraham Spector ,  Wanchao Ma ,  Ren-Rong Wang

    发明人： Abraham Spector ,  Wanchao Ma ,  Ren-Rong Wang

    IPC分类号： A61K38/41 ,  A61K38/44 ,  A61K38/00 ,  A61K38/16 ,  C07K5/00 ,  C07K7/00

    CPC分类号： A61K38/44 ,  A61K38/41

    摘要： This invention provides a method for treating a condition associated with oxidative stress in a subject which comprises administering to the subject an amount of a heme-peptide effective to treat the condition associated with oxidative stress in the subject. The subject may be a mammal. The mammal may be a human being. The condition associated with oxidative stress may be an inflammatory condition, an allergic condition or an auto-immune condition.

    摘要翻译： 本发明提供了一种治疗与受试者的氧化应激相关的病症的方法，其包括对受试者施用有效治疗与受试者的氧化应激相关的病症的量的血红素肽。 受试者可能是哺乳动物。 哺乳动物可能是人类。 与氧化应激相关的病症可能是炎性病症，过敏性疾病或自身免疫疾病。